Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
Noosa News24 hours agoDesign and construction integrity rewarded with national award
-
General19 hours agoThree maps that show the scale of the NSW flood disaster
-
General9 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News18 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws